Personensuche
Personensuche
Es wurde 1 Person gefunden.
Funktionen
-
Mitglied/er, Innere Klinik (Tumorforschung)
Aktuelle Veranstaltungen
-
2024 WS
- Arbeiten in den Laboratorien der Inneren Klinik (Tumorforschung)
- Wahlfach "Internistische Onkologie"
- Hämatologisches und onkologisches Mittagsseminar
- Blockpraktikum Innere Medizin (PV)
- Innere Medizin für Studierende im Praktischen Jahr (*)
- Differentialdiagnose Innere Krankheiten
- Molekulare Onkologie
Vergangene Veranstaltungen (max. 10)
-
2024 SS
- Wahlfach "Internistische Onkologie"
- Hämatologisches und onkologisches Mittagsseminar
- Arbeiten in den Laboratorien der Inneren Klinik (Tumorforschung)
- Blockpraktikum Innere Medizin (PV)
- Innere Medizin für Studierende im Praktischen Jahr (*)
- Differentialdiagnose Innere Krankheiten
- Molekulare Onkologie
-
2023 WS
Die folgenden Publikationen sind in der Online-Universitätsbibliographie der Universität Duisburg-Essen verzeichnet. Weitere Informationen finden Sie gegebenenfalls auch auf den persönlichen Webseiten der Person.
-
68Ga-Fibroblast Activation Protein Inhibitor PET/CT Improves Detection of Intermediate and Low-Grade Sarcomas and Identifies Candidates for Radiopharmaceutical TherapyIn: Journal of Nuclear Medicine (JNM) Jg. 65 (2024) Nr. 6, S. 880 - 887Online Volltext: dx.doi.org/
-
Avapritinib-based SAR studies unveil a binding pocket in KIT and PDGFRAIn: Nature Communications Jg. 15 (2024) Nr. 1, 63Online Volltext: dx.doi.org/ (Open Access)
-
Clinical Benefit of Avapritinib in KIT-Mutant Gastrointestinal Stromal Tumors : A Post Hoc Analysis of the Phase I NAVIGATOR and Phase I/II CS3007-001 StudiesIn: Clinical Cancer Research Jg. 30 (2024) Nr. 4, S. 719 - 728Online Volltext: dx.doi.org/
-
Correction to: Proteogenomic analysis reveals RNA as a source for tumor-agnostic neoantigen identificationIn: Nature Communications Jg. 15 (2024) Nr. 1, 2364Online Volltext: dx.doi.org/ (Open Access)
-
Fibroblast Activation Protein α-Directed Imaging and Therapy of Solitary Fibrous TumorIn: Journal of Nuclear Medicine (JNM) Jg. 65 (2024) Nr. 2, S. 252 - 257Online Volltext: dx.doi.org/ (Open Access)
-
Impact of CT and MRI in the diagnostic workup of malignant triton tumour : A monocentric analysis and review of the literatureIn: The British Journal of Radiology (BJR) Jg. 97 (2024) Nr. 1154, S. 430 - 438Online Volltext: dx.doi.org/ (Open Access)
-
KIT ATP-Binding Pocket/Activation Loop Mutations in GI Stromal Tumor : Emerging Mechanisms of Kinase Inhibitor EscapeIn: Journal of Clinical Oncology (JCO) Jg. 42 (2024) Nr. 12, S. 1439 - 1449Online Volltext: dx.doi.org/
-
Overall survival of patients with KIT-mutant metastatic GIST in the era of multiple kinase inhibitor availabilityIn: Journal of Cancer Research and Clinical Oncology Jg. 150 (2024) Nr. 11, 489Online Volltext: dx.doi.org/ (Open Access)
-
Prognostic factors in clear cell sarcoma: : an analysis of soft tissue sarcoma in 43 casesIn: Journal of Cancer Research and Clinical Oncology Jg. 150 (2024) Nr. 11, 494Online Volltext: dx.doi.org/ (Open Access)
-
Reply to Y. Xia et al [Comprehensive Discussions on KIT ATP-Binding Pocket/Activation Loop Mutations in Ripretinib Resistance]In: Journal of Clinical Oncology (JCO) Jg. 42 (2024) Nr. 27, S. 3260 - 3261Online Volltext: dx.doi.org/
-
Ripretinib versus sunitinib in gastrointestinal stromal tumor : ctDNA biomarker analysis of the phase 3 INTRIGUE trialIn: Nature Medicine Jg. 30 (2024) Nr. 2, S. 498 - 506Online Volltext: dx.doi.org/ (Open Access)
-
Survival of patients with ruptured gastrointestinal stromal tumour treated with adjuvant imatinib in a randomised trialIn: British Journal of Cancer (BJC) Jg. 131 (2024) Nr. 2, S. 299 - 304Online Volltext: dx.doi.org/ (Open Access)
-
The INSIGHT study : A randomized, Phase III study of ripretinib versus sunitinib for advanced gastrointestinal stromal tumor with KIT exon 11 + 17/18 mutationsIn: Future Oncology (2024) in pressOnline Volltext: dx.doi.org/ (Open Access)
-
The observational EURACAN prospective clinical registry dedicated to epithelioid hemangioendothelioma : The protocol of an international and collaborative effort on an ultra-rare entityIn: PLoS ONE Jg. 19 (2024) Nr. 8, e0308387Online Volltext: dx.doi.org/ (Open Access)
-
Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION) : a multicentre, randomised, double-blind, placebo-controlled, phase 3 trialIn: Lancet Jg. 403 (2024) Nr. 10445, S. 2709 - 2719Online Volltext: dx.doi.org/
-
A post hoc analysis of the EPAZ trial : The role of geriatric variables in elderly soft tissue sarcoma patients on toxicity and outcomeIn: European Journal of Cancer (EJC) Jg. 181 (2023) S. 145 - 154Online Volltext: dx.doi.org/
-
Best clinical management of tenosynovial giant cell tumour (TGCT) : A consensus paper from the community of expertsIn: Cancer Treatment Reviews Jg. 112 (2023) 102491Online Volltext: dx.doi.org/ (Open Access)
-
Circulating tumor DNA analysis of the phase III VOYAGER trial : KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor treated with avapritinib or regorafenibIn: Annals of Oncology Jg. 34 (2023) Nr. 7, S. 615 - 625Online Volltext: dx.doi.org/
-
Efficacy of immune checkpoint inhibitors in alveolar soft-part sarcoma : results from a retrospective worldwide registryIn: ESMO Open Jg. 8 (2023) Nr. 6, 102045Online Volltext: dx.doi.org/ (Open Access)
-
Electronic Patient-Reported Outcome Measures (ePROMs) Improve the Assessment of Underrated Physical and Psychological Symptom Burden among Oncological InpatientsIn: Cancers Jg. 15 (2023) Nr. 11, 3029Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Evaluation of the Effect of Photodynamic Therapy on CAM-Grown SarcomasIn: Bioengineering Jg. 10 (2023) Nr. 4, 464Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Fibroblast Activation Protein Inhibitor Theranostics : The Case for Use in SarcomaIn: PET Clinics Jg. 18 (2023) Nr. 3, S. 361 - 367Online Volltext: dx.doi.org/
-
Genetic susceptibility in children, adolescents, and young adults diagnosed with soft-tissue sarcomasIn: European Journal of Medical Genetics (EJMG) Jg. 66 (2023) Nr. 5, 104718Online Volltext: dx.doi.org/
-
Giant middle mediastinal lesions : when tumor size correlates with mesenchymal origin-a retrospective single-center analysisIn: Mediastinum Jg. 7 (2023) 8049Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Identification of novel pathogenic roles of BLZF1/ATF6 in tumorigenesis of gastrointestinal stromal tumor showing Golgi-localized mutant KITIn: Cell Death and Differentiation Jg. 30 (2023) Nr. 10, S. 2309 - 2321Online Volltext: dx.doi.org/ (Open Access)
-
KIT and PDGFRA Mutations and Survival of Gastrointestinal Stromal Tumor Patients Treated with Adjuvant Imatinib in a Randomized TrialIn: Clinical Cancer Research Jg. 29 (2023) Nr. 17, S. 3313 - 3319Online Volltext: dx.doi.org/ (Open Access)
-
Lokalisierte WeichgewebesarkomeIn: Best Practice Onkologie Jg. 18 (2023) Nr. 1-2, S. 44 - 58Online Volltext: dx.doi.org/
-
Molekularpathologisch determinierte multimodale Therapie gastrointestinaler StromatumorenIn: Die Onkologie Jg. 29 (2023) Nr. 2, S. 120 - 126Online Volltext: dx.doi.org/
-
New Prognostic Score (Essen Score) to Predict Postoperative Morbidity after Resection of Lung MetastasesIn: Cancers Jg. 15 (2023) Nr. 17, 4355Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label studyIn: European Journal of Cancer (EJC) Jg. 192 (2023) 113245Online Volltext: dx.doi.org/ (Open Access)
-
Pre-operative radiotherapy is associated with superior local relapse-free survival in advanced synovial sarcomaIn: Journal of Cancer Research and Clinical Oncology Jg. 149 (2023) Nr. 5, S. 1717 - 1731Online Volltext: dx.doi.org/ (Open Access)
-
Precision neuro-oncology : A pilot analysis of personalized treatment in recurrent gliomaIn: Journal of Cancer Research and Clinical Oncology Jg. 149 (2023) Nr. 7, S. 3513 - 3526Online Volltext: dx.doi.org/ (Open Access)
-
Proteogenomic analysis reveals RNA as a source for tumor-agnostic neoantigen identificationIn: Nature Communications Jg. 14 (2023) Nr. 1, S. 4632Online Volltext: dx.doi.org/ (Open Access)
-
Synovial sarcoma : characteristics, challenges, and evolving therapeutic strategiesIn: ESMO Open Jg. 8 (2023) Nr. 5, 101618Online Volltext: dx.doi.org/ (Open Access)
-
Tenosynovial Giant Cell Tumor Observational Platform Project (TOPP) Registry : A 2-Year Analysis of Patient-Reported Outcomes and Treatment StrategiesIn: The Oncologist Jg. 28 (2023) Nr. 6, S. E425 - E435Online Volltext: dx.doi.org/ (Open Access)
-
Treatment patterns and outcomes in patients with metastatic synovial sarcoma in France, Germany, Italy, Spain and the UKIn: Future Oncology Jg. 19 (2023) Nr. 18, S. 1261 - 1275Online Volltext: dx.doi.org/ (Open Access)
-
Zoledronic Acid Add-on Therapy for Standard-Risk Ewing Sarcoma Patients in the Ewing 2008R1 TrialIn: Clinical Cancer Research Jg. 29 (2023) Nr. 24, S. 5057 - 5068Online Volltext: dx.doi.org/
-
5-ALA-mediated fluorescence of musculoskeletal tumors in a chick chorio-allantoic membrane model : Preclinical in vivo qualification analysis as a fluorescence-guided surgery agent in Orthopedic OncologyIn: Journal of Orthopaedic Surgery and Research Jg. 17 (2022) Nr. 1, 34Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
58/w mit Unterbauchschmerzen, Inappetenz und Völlegefühl : Vorbereitung auf die Facharztprüfung: Fall 6In: Best Practice Onkologie Jg. 17 (2022) S. 434 - 444Online Volltext: dx.doi.org/
-
68Ga-FAPI as a Diagnostic Tool in Sarcoma : Data from the 68Ga-FAPI PET Prospective Observational TrialIn: Journal of Nuclear Medicine (JNM) Jg. 63 (2022) Nr. 1, S. 89 - 95Online Volltext: dx.doi.org/ (Open Access)
-
A multicenter, dose-finding, phase 1b study of imatinib in combination with alpelisib as third-line treatment in patients with advanced gastrointestinal stromal tumorIn: BMC Cancer Jg. 22 (2022) Nr. 1, 511Online Volltext: dx.doi.org/ (Open Access)
-
A phase Ib trial of combined PKC and MEK inhibition with sotrastaurin and binimetinib in patients with metastatic uveal melanomaIn: Frontiers in Oncology Jg. 12 (2022) 975642Online Volltext: dx.doi.org/ (Open Access)
-
A prospective real-world study of the diffuse-type tenosynovial giant cell tumor patient journey : A 2-year observational analysisIn: Journal of Surgical Oncology Jg. 126 (2022) Nr. 8, S. 1520 - 1532Online Volltext: dx.doi.org/ (Open Access)
-
Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations : Results from a Multi-institutional European Retrospective StudyIn: Clinical Cancer Research Jg. 28 (2022) Nr. 8, S. 1672 - 1679Online Volltext: dx.doi.org/ (Open Access)
-
Bcl-x(L) as prognostic marker and potential therapeutic target in cholangiocarcinomaIn: Liver International Jg. 42 (2022) Nr. 12, S. 2855 - 2870Online Volltext: dx.doi.org/ (Open Access)
-
Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma : Results from a Proof-of-Concept, Phase Ib StudyIn: Clinical Cancer Research Jg. 28 (2022) Nr. 6, S. 1087 - 1097Online Volltext: dx.doi.org/ (Open Access)
-
Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancersIn: Annals of Oncology Jg. 33 (2022) Nr. 11, S. 1186 - 1199Online Volltext: dx.doi.org/ (Open Access)
-
Correlation of Immunological and Molecular Profiles with Response to Crizotinib in Alveolar Soft Part Sarcoma : An Exploratory Study Related to the EORTC 90101 “CREATE” TrialIn: International Journal of Molecular Sciences (IJMS) Jg. 23 (2022) Nr. 10, 5689Online Volltext: dx.doi.org/ (Open Access)
-
Efficacy and safety of ripretinib in patients with KIT-altered metastatic melanomaIn: ESMO Open Jg. 7 (2022) Nr. 4, 100520Online Volltext: dx.doi.org/ (Open Access)
-
Gastrointestinal Stromal Tumor : New Insights for a Multimodal ApproachIn: Surgical Oncology Clinics of North America Jg. 31 (2022) Nr. 3, S. 431 - 446Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Gastrointestinal stromal tumours : ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-upIn: Annals of Oncology Jg. 33 (2022) Nr. 1, S. 20 - 33Online Volltext: dx.doi.org/ (Open Access)
-
Gene expression-based prediction of pazopanib efficacy in sarcomaIn: European Journal of Cancer (EJC) Jg. 172 (2022) S. 107 - 118Online Volltext: dx.doi.org/
-
High-Dose Treosulfan and Melphalan as Consolidation Therapy Versus Standard Therapy for High-Risk (Metastatic) Ewing SarcomaIn: Journal of Clinical Oncology (JCO) Jg. 40 (2022) Nr. 21, 2307-2320Online Volltext: dx.doi.org/ (Open Access)
-
Initial Clinical Experience with ⁹⁰Y-FAPI-46 Radioligand Therapy for Advanced-Stage Solid Tumors : A Case Series of 9 PatientsIn: Journal of Nuclear Medicine (JNM) Jg. 63 (2022) Nr. 5, S. 727 - 734Online Volltext: dx.doi.org/ (Open Access)
-
Is preoperative CT-guided biopsy a valuable tool in the diagnostic workup of patients with visceral and retroperitoneal sarcoma?In: European Journal of Radiology Jg. 155 (2022) 110470Online Volltext: dx.doi.org/
-
Medikamentöse Therapie retroperitonealer WeichteilsarkomeIn: Der Chirurg Jg. 93 (2022) Nr. 1, S. 40 - 47Online Volltext: dx.doi.org/
-
New Tyrosine Kinase Inhibitors for the Treatment of Gastrointestinal Stromal TumorsIn: Current Oncology Reports Jg. 24 (2022) Nr. 2, S. 151 - 159Online Volltext: dx.doi.org/
-
Patient-reported outcomes in individuals with advanced gastrointestinal stromal tumor treated with ripretinib in the fourth-line setting : analysis from the phase 3 INVICTUS trialIn: BMC Cancer Jg. 22 (2022) Nr. 1, 1302Online Volltext: dx.doi.org/ (Open Access)
-
Plasma Sequencing for Patients with GIST : Limitations and Opportunities in an Academic SettingIn: Cancers Jg. 14 (2022) Nr. 22, 5496Online Volltext: dx.doi.org/ (Open Access)
-
Prognostic Factors for Leiomyosarcoma with Isolated Metastases to the Lungs : Impact of MetastasectomyIn: Annals of Surgical Oncology Jg. 29 (2022) Nr. 7, S. 4429 - 4436Online Volltext: dx.doi.org/ (Open Access)
-
Proton Therapy for Primary Bone Malignancy of the Pelvic and Lumbar Region : Data From the Prospective Registries ProReg and KiProRegIn: Frontiers in Oncology Jg. 12 (2022) 805051Online Volltext: dx.doi.org/ (Open Access)
-
Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute LeukemiaIn: Clinical Cancer Research Jg. 28 (2022) Nr. 5, S. 870 - 881Online Volltext: dx.doi.org/ (Open Access)
-
Reversible occlusion of the pulmonary vasculature by transarterial embolisation with degradable starch microspheres : preclinical assessment in a human isolated lung perfusion modelIn: European Radiology Experimental Jg. 6 (2022) Nr. 1, 6Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Ripretinib Versus Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumor after Treatment with Imatinib (INTRIGUE) : A Randomized, Open-Label, Phase III TrialIn: Journal of Clinical Oncology (JCO) Jg. 40 (2022) Nr. 34, S. 3918 - 3928Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer EntitiesIn: Clinical Cancer Research Jg. 28 (2022) Nr. 19, S. 4346 - 4353Online Volltext: dx.doi.org/ (Open Access)
-
Transcriptome-Wide Gene Expression Profiles from FFPE Materials Based on a Nuclease Protection Assay Reveals Significantly Different Patterns between Synovial Sarcomas and Morphologic MimickersIn: Cancers Jg. 14 (2022) Nr. 19, 4737Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
58/w mit Unterbauchschmerzen, Inappetenz und Völlegefühl : Vorbereitung auf die Facharztprüfung: Fall 6In: Der Onkologe Jg. 27 (2021) S. 38 - 43Online Volltext: dx.doi.org/
-
Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor : A Randomized, Open-Label Phase III StudyIn: Journal of Clinical Oncology (JCO) Jg. 39 (2021) Nr. 28, S. 3128 - 3139Online Volltext: dx.doi.org/ (Open Access)
-
Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least Three Prior Lines of TherapyIn: The Oncologist Jg. 26 (2021) Nr. 4, S. e639 - e649Online Volltext: dx.doi.org/ (Open Access)
-
Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trialIn: European Journal of Cancer (EJC) Jg. 145 (2021) S. 132 - 142Online Volltext: dx.doi.org/ (Open Access)
-
Benefit of pazopanib in advanced gastrointestinal stromal tumours: results from a phase II trial (SSG XXI, PAGIST)In: ESMO Open Jg. 6 (2021) Nr. 4, 100217Online Volltext: dx.doi.org/ (Open Access)
-
Bone sarcomas : ESMO–EURACAN–GENTURIS–ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-upIn: Annals of Oncology Jg. 32 (2021) Nr. 12, S. 1520 - 1536Online Volltext: dx.doi.org/ (Open Access)
-
Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS StudyIn: Clinical Cancer Research Jg. 27 (2021) Nr. 23, S. 6333 - 6342Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor : An Analysis of the INVICTUS StudyIn: The Oncologist Jg. 26 (2021) Nr. 11, S. e2053 - e2060Online Volltext: dx.doi.org/ (Open Access)
-
Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare CancersIn: Cancer Discovery Jg. 11 (2021) Nr. 11, S. 2780 - 2795Online Volltext: dx.doi.org/ (Open Access)
-
Early and Next-Generation KIT/PDGFRA Kinase Inhibitors and the Future of Treatment for Advanced Gastrointestinal Stromal TumorIn: Frontiers in Oncology Jg. 11 (2021) 672500Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Epithelioid hemangioendothelioma, an ultra-rare cancer : A consensus paper from the community of expertsIn: ESMO Open Jg. 6 (2021) Nr. 3, 100170Online Volltext: dx.doi.org/ (Open Access)
-
Evaluation of the predictive potential of 18F-FDG PET and DWI data sets for relevant prognostic parameters of primary soft-tissue sarcomasIn: Cancers Jg. 13 (2021) Nr. 11, 2753Online Volltext: dx.doi.org/ (Open Access)
-
Evaluation of ¹⁸F-FDG PET and DWI Datasets for Predicting Therapy Response of Soft-Tissue Sarcomas Under Neoadjuvant Isolated Limb PerfusionIn: Journal of Nuclear Medicine (JNM) Jg. 62 (2021) Nr. 3, S. 348 - 353Online Volltext: dx.doi.org/ (Open Access)
-
Ewing Sarcoma—Diagnosis, Treatment, Clinical Challenges and Future PerspectivesIn: Journal of Clinical Medicine (JCM) Jg. 10 (2021) Nr. 8, 1685Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
GNA14, GNA11, and GNAQ Mutations Are Frequent in Benign but Not Malignant Cutaneous Vascular TumorsIn: Frontiers in Genetics Jg. 12 (2021) 663272Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Kutanes Angiosarkom mit klinischem Bild eines Quincke-ÖdemsIn: Der Hautarzt Jg. 72 (2021) Nr. 9, S. 801 - 804Online Volltext: dx.doi.org/ (Open Access)
-
Laktatdehydrogenase vor transarterieller hepatischer Chemoperfusion prognostiziert das Überleben und den Tumorprogress bei Patienten mit Lebermetastasen bei AderhautmelanomIn: RöFo: Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren Jg. 193 (2021) Nr. 06, S. 683 - 691Online Volltext: dx.doi.org/ (Open Access)
-
Localized Angiosarcoma, Not One Disease : A Retrospective Single-Center Study on Prognosis Depending on the Primary Site and EtiologyIn: Sarcoma Jg. 2021 (2021) 9960085Online Volltext: dx.doi.org/ (Open Access)
-
Number of metastases and their response to chemotherapy impact survival of patients with isolated lung metastases from bone-derived sarcomaIn: BMC Cancer Jg. 21 (2021) Nr. 1, 375Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Optimal Avapritinib Treatment Strategies for Patients with Metastatic or Unresectable Gastrointestinal Stromal TumorsIn: The Oncologist Jg. 26 (2021) Nr. 4, S. e622 - e631Online Volltext: dx.doi.org/ (Open Access)
-
Pexidartinib Long-Term Hepatic Safety Profile in Patients with Tenosynovial Giant Cell TumorsIn: The Oncologist Jg. 26 (2021) Nr. 5, S. e863 - e873Online Volltext: dx.doi.org/ (Open Access)
-
Pharmacokinetic–pharmacodynamic guided optimisation of dose and schedule of CGM097, an HDM2 inhibitor, in preclinical and clinical studiesIn: British Journal of Cancer (BJC) Jg. 125 (2021) Nr. 5, S. 687 - 698Online Volltext: dx.doi.org/ (Open Access)
-
Predictive impact of the inflammation-based indices in uveal melanoma liver metastases treated with transarterial hepatic chemoperfusionIn: Radiology and Oncology Jg. 55 (2021) Nr. 3, S. 347 - 353Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Relationships between highly recurrent tumor suppressor alterations in 489 leiomyosarcomasIn: Cancer Jg. 127 (2021) Nr. 15, S. 2666 - 2673Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Reply to E. Younger et al, V. Sharma et al, and M. Uchihara et alIn: Journal of Clinical Oncology (JCO) Jg. 39 (2021) Nr. 7, S. 864 - 865Online Volltext: dx.doi.org/ (Open Access)
-
Resistance to avapritinib in pdgfra-driven gist is caused by secondary mutations in the pdgfra kinase domainIn: Cancer Discovery Jg. 11 (2021) Nr. 1, S. 108 - 125Online Volltext: dx.doi.org/ (Open Access)
-
Soft tissue and visceral sarcomas : ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆In: Annals of Oncology Jg. 32 (2021) Nr. 11, 1348-1365Online Volltext: dx.doi.org/ (Open Access)
-
Surgical Treatment for Primary Chest Wall Sarcoma: A Single-Institution StudyIn: Journal of Surgical Research Jg. 260 (2021) S. 149 - 154Online Volltext: dx.doi.org/
-
The diffuse-type tenosynovial giant cell tumor (dt-TGCT) patient journey : a prospective multicenter studyIn: Orphanet Journal of Rare Diseases Jg. 16 (2021) Nr. 1, S. 191Online Volltext: dx.doi.org/ (Open Access)
-
The effect of adjuvant therapies on long-term outcome for primary resected synovial sarcoma in a series of mainly children and adolescentsIn: Journal of Cancer Research and Clinical Oncology Jg. 147 (2021) Nr. 12, S. 3735 - 3747Online Volltext: dx.doi.org/ (Open Access)
-
Treatment of angiosarcoma with pazopanib and paclitaxel : Results of the eva (evaluation of votrient® in angiosarcoma) phase ii trial of the german interdisciplinary sarcoma group (gisg-06)In: Cancers Jg. 13 (2021) Nr. 6, S. 1223Online Volltext: dx.doi.org/ (Open Access)
-
Tropomyosin receptor kinases in sarcomas - of joy and despairIn: Current Opinion in Oncology Jg. 33 (2021) Nr. 4, S. 336 - 344Online Volltext: dx.doi.org/
-
Tumor DNA methylation profiles correlate with response to anti-PD-1 immune checkpoint inhibitor monotherapy in sarcoma patientsIn: Journal for ImmunoTherapy of Cancer Jg. 9 (2021) Nr. 3, S. e001458Online Volltext: dx.doi.org/ (Open Access)
-
Ameloblastic fibrosarcoma : clinicopathological and molecular analysis of seven cases highlighting frequent BRAF and occasional NRAS mutationsIn: Histopathology Jg. 76 (2020) Nr. 6, S. 814 - 821Online Volltext: dx.doi.org/ (Open Access)
-
Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR) : A multicentre, open-label, phase 1 trialIn: The Lancet Oncology Jg. 21 (2020) Nr. 7, S. 935 - 946Online Volltext: dx.doi.org/
-
Fatal swelling of the groin – Clear cell sarcoma : A rare but important differential diagnosis to malignant melanomaIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 18 (2020) Nr. 10, S. 1165 - 1168Online Volltext: dx.doi.org/ (Open Access)
-
Germline SDHB-inactivating mutation in gastric spindle cell sarcomaIn: Genes, Chromosomes and Cancer Jg. 59 (2020) Nr. 10, S. 601 - 608Online Volltext: dx.doi.org/
-
Intrigue : Phase III study of ripretinib versus sunitinib in advanced gastrointestinal stromal tumor after imatinibIn: Future Oncology Jg. 16 (2020) Nr. 1, S. 4251 - 4264Online Volltext: dx.doi.org/ (Open Access)
-
Multimodality treatment including surgery for primary pulmonary sarcoma : Size does matterIn: Journal of Surgical Oncology Jg. 122 (2020) Nr. 3, S. 506 - 514Online Volltext: dx.doi.org/ (Open Access)
-
Predicting outcome of epilepsy surgery in clinical practice : Prediction models vs. clinical acumenIn: Seizure Jg. 76 (2020) S. 79 - 83Online Volltext: dx.doi.org/ (Open Access)
-
Quality of life (QoL) and self-reported function with ripretinib in ≥4th-line therapy for patients with gastrointestinal stromal tumors (GIST) : Analyses from INVICTUSIn: Journal of Clinical Oncology (JCO) Jg. 38 (2020) Nr. 15_Suppl., S. 11535Online Volltext: dx.doi.org/
-
Randomised phase II trial of trofosfamide vs. doxorubicin in elderly patients with untreated metastatic soft-tissue sarcomaIn: European Journal of Cancer (EJC) Jg. 124 (2020) S. 152 - 160Online Volltext: dx.doi.org/ Online Volltext
-
Randomized Comparison of Pazopanib and Doxorubicin as First-Line Treatment in Patients with Metastatic Soft Tissue Sarcoma Age 60 Years or Older : Results of a German Intergroup StudyIn: Journal of Clinical Oncology (JCO) Jg. 38 (2020) Nr. 30, S. 3555 - 3564Online Volltext: dx.doi.org/
-
Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS) : a double-blind, randomised, placebo-controlled, phase 3 trialIn: The Lancet Oncology Jg. 21 (2020) Nr. 7, S. 923 - 934Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Safety profile of ripretinib, including impact of alopecia, and Palmar-Plantar Erythrodysesthesia Syndrome (PPES) on patient-reported outcomes (PROs), in ≥ fourth-line advanced gastrointestinal stromal tumors (GIST) : Analyses from INVICTUSIn: Journal of Clinical Oncology (JCO) Jg. 38 (2020) Nr. 15_Suppl., S. 11539Online Volltext: dx.doi.org/
-
Survival Outcomes Associated with 3 Years vs 1 Year of Adjuvant Imatinib for Patients with High-Risk Gastrointestinal Stromal Tumors : An Analysis of a Randomized Clinical Trial after 10-Year Follow-upIn: JAMA Oncology Jg. 6 (2020) Nr. 8, S. 1241 - 1246Online Volltext: dx.doi.org/ (Open Access)
-
Synovial sarcoma disease characteristics and primary tumor sites differ between patient age groups : a report of the Cooperative Weichteilsarkom Studiengruppe (CWS)In: Journal of Cancer Research and Clinical Oncology (2020)Online Volltext: dx.doi.org/
-
Targeting Her2-insYVMA with Covalent Inhibitors-A Focused Compound Screening and Structure-Based Design ApproachIn: Journal of Medicinal Chemistry Jg. 63 (2020) Nr. 20, S. 11725 - 11755Online Volltext: dx.doi.org/
-
Which Factors Are Associated with Local Control and Survival of Patients with Localized Pelvic Ewing's Sarcoma? : A Retrospective Analysis of Data from the Euro-EWING99 TrialIn: Clinical Orthopaedics and Related Research Jg. 478 (2020) Nr. 2, S. 290 - 302Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
18F-FDG PET/MRI for Therapy Response Assessment of Isolated Limb Perfusion in Patients with Soft-Tissue SarcomasIn: Journal of Nuclear Medicine (JNM) Jg. 60 (2019) Nr. 11, S. 1537 - 1542Online Volltext: dx.doi.org/ (Open Access)
-
Avelumab in patients with previously treated metastatic melanoma : Phase 1b results from the JAVELIN Solid Tumor trialIn: Journal for ImmunoTherapy of Cancer Jg. 7 (2019) Nr. 1, S. 12Online Volltext: dx.doi.org/ (Open Access)
-
Circulating cKIT and PDGFRA DNA indicates disease activity in Gastrointestinal Stromal Tumor (GIST)In: International Journal of Cancer Jg. 125 (2019) Nr. 8, S. 2292 - 2303Online Volltext: dx.doi.org/ (Open Access)
-
Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumoursIn: British Journal of Cancer (BJC) Jg. 120 (2019) Nr. 6, S. 612 - 620Online Volltext: dx.doi.org/ (Open Access)
-
Correction: Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumoursIn: British Journal of Cancer (BJC) Jg. 121 (2019) Nr. 218,Online Volltext: dx.doi.org/ (Open Access)
-
Defective homologous recombination DNA repair as therapeutic target in advanced chordomaIn: Nature Communications Jg. 10 (2019) Nr. 1, S. 1635Online Volltext: dx.doi.org/ (Open Access)
-
Desmoplastic small round cell tumors : Multimodality treatment and new risk factorsIn: Cancer Medicine Jg. 8 (2019) Nr. 2, S. 527 - 542Online Volltext: dx.doi.org/ (Open Access)
-
Eribulin versus dacarbazine in patients with leiomyosarcoma : subgroup analysis from a phase 3, open-label, randomised studyIn: British Journal of Cancer (BJC) Jg. 120 (2019) Nr. 11, S. 1026 - 1032Online Volltext: dx.doi.org/ (Open Access)
-
Genomic aberrations in cell cycle genes predict progression of KIT-mutant gastrointestinal stromal tumors (GISTs)In: Clinical Sarcoma Research Jg. 9 (2019) 3Online Volltext: dx.doi.org/ (Open Access)
-
Imatinib und darüber hinaus : Was ist wichtig für die Chirurgie?In: Der Chirurg Jg. 90 (2019) Nr. 6, S. 462 - 469Online Volltext: dx.doi.org/
-
Inhibition of osimertinib-resistant epidermal growth factor receptor EGFR-T790M/C797SIn: Chemical Science Jg. 10 (2019) Nr. 46, S. 10789 - 10801Online Volltext: dx.doi.org/ (Open Access)
-
KIT-Dependent and KIT-Independent Genomic Heterogeneity of Resistance in Gastrointestinal Stromal Tumors : TORC1/2 Inhibition as Salvage StrategyIn: Molecular Cancer Therapeutics Jg. 18 (2019) Nr. 11, S. 1985 - 1996Online Volltext: dx.doi.org/ (Open Access)
-
New therapeutic agents in gastrointestinal stromal tumoursIn: Current Opinion in Oncology Jg. 31 (2019) Nr. 4, S. 322 - 328Online Volltext: dx.doi.org/
-
Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN) : a randomised phase 3 trialIn: Lancet Jg. 394 (2019) Nr. 10197, S. 478 - 487Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
S1 Guidelines for Dermatofibrosarcoma Protuberans (DFSP) - Update 2018In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 17 (2019) Nr. 6, S. 663 - 668Online Volltext: dx.doi.org/
-
S1-Leitlinie Dermatofibrosarcoma Protuberans (DFSP) - Update 2018In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 17 (2019) Nr. 6, S. 663 - 668Online Volltext: dx.doi.org/
-
Safety and efficacy of Pazopanib in advanced soft tissue sarcoma : PALETTE (EORTC 62072) subgroup analysesIn: BMC Cancer Jg. 19 (2019) Nr. 1, 794Online Volltext: dx.doi.org/ (Open Access)
-
Safety of Imatinib Mesylate in a Multicenter Expanded Access Program in Adult Patients with Gastrointestinal Stromal Tumors in the Adjuvant SettingIn: Oncology Research and Treatment Jg. 42 (2019) Nr. 12, S. 629 - 634Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Systemische Therapie von Sarkomen : Neue Biomarker und TherapiestrategienIn: Der Pathologe Jg. 40 (2019) Nr. 4, S. 436 - 442Online Volltext: dx.doi.org/
-
Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3 : European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 'CREATE'In: Annals of Oncology Jg. 29 (2018) Nr. 3, S. 758 - 765Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Avelumab in patients with previously treated metastatic adrenocortical carcinoma : Phase 1b results from the JAVELIN solid tumor trialIn: Journal for ImmunoTherapy of Cancer Jg. 6 (2018) Nr. 1, S. 111Online Volltext: dx.doi.org/ (Open Access)
-
Avelumab in patients with previously treated metastatic melanoma : Phase 1b results from the JAVELIN Solid Tumor trial.In: Journal of Clinical Oncology (JCO) Jg. 36 (2018) Nr. 5 Suppl., S. 191Online Volltext: dx.doi.org/ (Open Access)
-
Bone sarcomas : ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-upIn: Annals of Oncology Jg. 29 (2018) Nr. Suppl. 4, S. iv79 - iv95Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Correlation of ctDNA and response in patients (pts) with PDGFRα D842 GIST treated with avapritinibIn: Annals of Oncology Jg. 29 (2018) Nr. Suppl. 8, S. viii584Online Volltext: dx.doi.org/ (Open Access)
-
Dramatic response of a PD-L1- positive advanced angiosarcoma of the scalp to pembrolizumabIn: JCO Precision Oncology Jg. 2 (2018)Online Volltext: dx.doi.org/
-
Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-upIn: Annals of Oncology Jg. 29 (2018) Nr. Suppl. 4, S. iv68 - iv78Online Volltext: dx.doi.org/ (Open Access)
-
Head and Neck Kaposi Sarcoma : Clinicopathological Analysis of 11 CasesIn: Head and Neck Pathology Jg. 12 (2018) Nr. 4, S. 511 - 516Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Health-related quality of life (HR-QoL) in elderly soft tissue sarcoma (STS) patients from the randomized phase II EPAZ study comparing pazopanib (PAZ) and doxorubicin (DOX) in first lineIn: Annals of Oncology Jg. 29 (2018) Nr. Suppl. 8, S. viii577Online Volltext: dx.doi.org/ (Open Access)
-
High-dose chemotherapy and blood autologous stem-cell rescue compared with standard chemotherapy in localized high-risk ewing sarcoma : Results of Euro-E.W.I.N.G.99 and Ewing-2008In: Journal of Clinical Oncology (JCO) Jg. 36 (2018) Nr. 31, S. 3110 - 3119Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Integrative genomic and transcriptomic analysis of leiomyosarcomaIn: Nature Communications Jg. 9 (2018) Nr. 1, S. 144Online Volltext: dx.doi.org/ (Open Access)
-
Konjunktivales Melanom : Standardisiertes Vorgehen in Diagnostik, Therapie und NachsorgeIn: Der Ophthalmologe: Zeitschrift der Deutschen Ophthalmologischen Gesellschaft Jg. 115 (2018) Nr. 6, S. 489 - 498Online Volltext: dx.doi.org/
-
Long-term outcome of dasatinib first-line treatment in gastrointestinal stromal tumor : A multicenter, 2-stage phase 2 trial (Swiss Group for Clinical Cancer Research 56/07)In: Cancer Jg. 124 (2018) Nr. 7, S. 1449 - 1454Online Volltext: dx.doi.org/ (Open Access)
-
Options for treating different soft tissue sarcoma subtypesIn: Future Oncology Jg. 14 (2018) Nr. 10S, S. 25 - 49Online Volltext: dx.doi.org/
-
Pre- and Postoperative Chemotherapy in Localized Extremity Soft Tissue Sarcoma : A European Organization for Research and Treatment of Cancer Expert SurveyIn: The Oncologist Jg. 23 (2018) Nr. 4, S. 461 - 467Online Volltext: dx.doi.org/ (Open Access)
-
Randomized Phase 2 Study of Trabectedin/Olaparib Compared to Physicians Choice in Subjects with Previously Treated Advanced or Recurrent Solid Tumors Haboring DNA Repair Deficiencies (DKTK/NCT-PMO-1603, TOP-ART)In: Oncology Research and Treatment Jg. 41 (2018) Nr. Suppl. 1, S. 120 - 121
-
Recurrence of Ewing sarcoma : Is detection by imaging follow-up protocol associated with survival advantage?In: Pediatric Blood and Cancer Jg. 65 (2018) Nr. 7, e27011Online Volltext: dx.doi.org/
-
Soft tissue and visceral sarcomas : ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-upIn: Annals of Oncology Jg. 29 (2018) Nr. Suppl. 4, S. iv51 - iv67Online Volltext: dx.doi.org/ (Open Access)
-
Survivin is a novel transcription regulator of KIT and is downregulated by miRNA-494 in gastrointestinal stromal tumorsIn: International Journal of Cancer Jg. 142 (2018) Nr. 10, S. 2080 - 2093Online Volltext: dx.doi.org/ (Open Access)
-
The Interdisciplinary Diagnosis and Treatment of Intraocular TumorsIn: Deutsches Ärzteblatt international Jg. 115 (2018) Nr. 7, S. 106 - 111Online Volltext: dx.doi.org/ (Open Access)
-
The tyrosine kinase inhibitor crizotinib does not have clinically meaningful activity in heavily pre-treated patients with advanced alveolar rhabdomyosarcoma with FOXO rearrangement: European Organisation for Research and Treatment of Cancer phase 2 trial 90101 ‘CREATE’In: European Journal of Cancer (EJC) Jg. 94 (2018) S. 156 - 167Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Translational Insights into Gastrointestinal Stromal Tumor and Current Clinical AdvancesIn: Annals of Oncology Jg. 29 (2018) Nr. 10, S. 2037 - 2045Online Volltext: dx.doi.org/ (Open Access)
-
VOYAGER : An open-label, randomised, phase III study of avapritinib vs regorafenib in patients (pts) with locally advanced (adv) metastatic or unresectable gastrointestinal stromal tumour (GIST)In: Annals of Oncology Jg. 29 (2018) Nr. Suppl. 8, S. viii595Online Volltext: dx.doi.org/ (Open Access)
-
Validating comprehensive next-generation sequencing results for precision oncology : The NCT/DKTK molecularly aided stratification for tumor eradication research experienceIn: JCO Precision Oncology Jg. 2 (2018) S. 1 - 13Online Volltext: dx.doi.org/ (Open Access)
-
A phase II study of a human anti-PDGFRα monoclonal antibody (olaratumab, IMC-3G3) in previously treated patients with metastatic gastrointestinal stromal tumorsIn: Annals of Oncology Jg. 28 (2017) Nr. 3, S. 541 - 546Online Volltext: dx.doi.org/ (Open Access)
-
Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations : European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'In: Annals of Oncology Jg. 28 (2017) Nr. 12, S. 3000 - 3008Online Volltext: dx.doi.org/
-
Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification : EORTC 90101 CREATE trialIn: European Journal of Cancer (EJC) Jg. 87 (2017)Online Volltext: dx.doi.org/
-
Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinibIn: British Journal of Cancer (BJC) Jg. 117 (2017) S. 1278 - 1285Online Volltext: dx.doi.org/ (Open Access)
-
Effect of KIT and PDGFRA mutations on survival in patients with gastrointestinal stromal tumors treated with adjuvant imatinib : An exploratory analysis of a randomized clinical trialIn: JAMA Oncology Jg. 3 (2017) Nr. 5, S. 602 - 609Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Eltrombopag for thrombocytopenia in patients with advanced solid tumors receiving gemcitabine-based chemotherapy : a randomized, placebo-controlled phase 2 studyIn: International Journal of Hematology Jg. 106 (2017) Nr. 6, S. 765 - 776Online Volltext: dx.doi.org/
-
Erratum zu: Isolierte Extremitätenperfusion bei Liposarkomen. Histopathologisches Ansprechen und Subgruppenanalyse nach TNF-Melphalan-ILPIn: Der Chirurg Jg. 88 (2017) Nr. 5, S. 437Online Volltext: dx.doi.org/
-
Ictal conduction aphasia and ictal angular gyrus syndrome as rare manifestations of epilepsy : the importance of ictal testing during video-EEG monitoringIn: Epilepsy & Behavior Case Reports Jg. 8 (2017) S. 55 - 62Online Volltext: dx.doi.org/ (Open Access)
-
Imatinib induces sustained progression arrest in RECIST progressive desmoid tumours : Final results of a phase II study of the German Interdisciplinary Sarcoma Group (GISG)In: European Journal of Cancer (EJC) Jg. 76 (2017) S. 60 - 67Online Volltext: dx.doi.org/
-
Indazole-Based covalent inhibitors to target drug-resistant epidermal growth factor receptorIn: Journal of Medicinal Chemistry Jg. 60 (2017) Nr. 6, S. 2361 - 2372Online Volltext: dx.doi.org/
-
Inhibitors to overcome secondary mutations in the stem cell factor receptor KITIn: Journal of Medicinal Chemistry Jg. 60 (2017) Nr. 21, S. 8801 - 8815Online Volltext: dx.doi.org/
-
Integrated 18F–FDG PET/MRI compared to MRI alone for identification of local recurrences of soft tissue sarcomas : a comparison trialIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 44 (2017) Nr. 11, S. 1823 - 1831Online Volltext: dx.doi.org/
-
Isolierte Extremitätenperfusion bei Liposarkomen : Histopathologisches Ansprechen und Subgruppenanalyse nach TNF-Melphalan-ILPIn: Der Chirurg Jg. 88 (2017) Nr. 5, S. 429 - 436Online Volltext: dx.doi.org/
-
Lower limb function and quality of life after ILP for soft-tissue sarcomaIn: World Journal of Surgical Oncology Jg. 15 (2017) Nr. 1, S. 84Online Volltext: dx.doi.org/ (Open Access)
-
MAX inactivation is an early event in GIST development that regulates p16 and cell proliferationIn: Nature Communications Jg. 8 (2017) S. 14674Online Volltext: dx.doi.org/ (Open Access)
-
Overall survival of patients with leiomyosarcomaIn: Oncology Research and Treatment Jg. 40 (2017) Nr. Suppl.3, S. 112 - 112
-
Preclinical models for translational sarcoma researchIn: Current Opinion in Oncology Jg. 29 (2017) Nr. 4, S. 275 - 285Online Volltext: dx.doi.org/
-
Pulmonary metastasectomy for sarcoma-Essen experienceIn: Journal of Thoracic Disease Jg. 9 (2017) S. S1278 - S1281Online Volltext: dx.doi.org/ (Open Access)
-
Results for patients with sarcoma not otherwise specified and other diagnoses than Ewing sarcoma treated according to the Euro-EWING 99 trialIn: Pediatric Blood and Cancer Jg. 64 (2017) Nr. 10, S. e26524Online Volltext: dx.doi.org/
-
STREAM : A randomized discontinuation, blinded, placebo-controlled phase II study of sorafenib (5) treatment of chemonaive patients (pts) with metastatic uveal melanoma (MUM)In: Journal of Clinical Oncology (JCO) Jg. 35 (2017) Nr. 15, S. 9511Online Volltext: dx.doi.org/
-
Sustained mutant KIT activation in the Golgi complex is mediated by PKC-θ in gastrointestinal stromal tumorsIn: Clinical Cancer Research Jg. 23 (2017) Nr. 3, S. 845 - 856Online Volltext: dx.doi.org/
-
1401PD - Subgroup analysis of leiomyosarcoma (LMS) patients (pts) from a phase 3, open-label, randomized study of eribulin (ERI) versus dacarbazine (DTIC) in pts with advanced liposarcoma (LPS) and LMSIn: Annals of Oncology Jg. 27 (2016) Nr. Suppl. 6, S. vi485Online Volltext: dx.doi.org/ (Open Access)
-
A phase I, open-label, multi-center, dose escalation study of oral NVP-CGM097, a p53/HDM2-protein-protein interaction inhibitor, in adult patients with selected advanced solid tumorsIn: Annals of Oncology Jg. 27 (2016) Nr. Suppl. 6, S. 366PDOnline Volltext: dx.doi.org/
-
Adjuvant Imatinib for High-Risk GI Stromal Tumor : Analysis of a Randomized TrialIn: Journal of Clinical Oncology (JCO) Jg. 34 (2016) Nr. 3, S. 244 - 250Online Volltext: dx.doi.org/
-
Correlation of CTNNB1 Mutation Status with Progression Arrest Rate in RECIST Progressive Desmoid-Type Fibromatosis Treated with Imatinib : Translational Research Results from a Phase 2 Study of the German Interdisciplinary Sarcoma Group (GISG-01)In: Annals of Surgical Oncology Jg. 23 (2016) Nr. 6, S. 1924 - 1927Online Volltext: dx.doi.org/
-
Dose- and regimen-finding phase I study of NVP-HDM201 in patients (pts) with TP53 wild-type (wt) advanced tumorsIn: European Journal of Cancer (EJC) Jg. 69 (2016) Nr. Suppl. 1, S. S128 - S129Online Volltext: dx.doi.org/
-
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma : a randomised, open-label, multicentre, phase 3 trialIn: Lancet Jg. 387 (2016) Nr. 10028, S. 1629 - 1637Online Volltext: dx.doi.org/
-
HR23b expression is a potential predictive biomarker for HDAC inhibitor treatment in mesenchymal tumours and is associated with response to vorinostatIn: The Journal of Pathology: Clinical Research Jg. 2 (2016) Nr. 2, S. 59 - 71Online Volltext: dx.doi.org/ (Open Access)
-
Inhibitor of Apoptosis Proteins (IAPs) are commonly dysregulated in GIST and can be pharmacologically targeted to enhance the pro-apoptotic activity of imatinibIn: OncoTarget Jg. 7 (2016) Nr. 27, S. 41390 - 41403Online Volltext: dx.doi.org/ (Open Access)
-
Insight into the Inhibition of Drug-Resistant Mutants of the Receptor Tyrosine Kinase EGFRIn: Angewandte Chemie International Edition Jg. 55 (2016) Nr. 36, S. 10909 - 10912Online Volltext: dx.doi.org/
-
Molecular subtypes of gastrointestinal stromal tumor requiring specific treatmentsIn: Current Opinion in Oncology Jg. 28 (2016) Nr. 4, S. 331 - 337Online Volltext: dx.doi.org/
-
Needle biopsy through the abdominal wall for the diagnosis of gastrointestinal stromal tumour – Does it increase the risk for tumour cell seeding and recurrence?In: European Journal of Cancer (EJC) Jg. 59 (2016) S. 128 - 133Online Volltext: dx.doi.org/ (Open Access)
-
Plastische Chirurgie in der Palliation – Bericht des Consensus-Workshops im Rahmen der 37. Jahrestagung der Deutschsprachigen Gemeinschaft für Mikrochirurgie der peripheren Nerven und Gefäße (DAM) 2015 in BochumIn: Handchirurgie, Mikrochirurgie, plastische Chirurgie Jg. 48 (2016) Nr. 6, S. 340 - 345Online Volltext: dx.doi.org/
-
Preliminary safety and activity in a first-in-human phase 1 study of BLU-285, a potent, highly-selective inhibitor of KIT and PDGFRα activation loop mutants in advanced gastrointestinal stromal tumor (GIST)In: European Journal of Cancer (EJC) Jg. 69 (2016) Nr. Suppl. 1, S. 4Online Volltext: dx.doi.org/
-
The novel pyrrolo-1,5-benzoxazepine, PBOX-15, synergistically enhances the apoptotic efficacy of imatinib in gastrointestinal stromal tumours; suggested mechanism of action of PBOX-15In: Investigational New Drugs: The Journal of New Anticancer Agents Jg. 34 (2016) Nr. 2, S. 159 - 167Online Volltext: dx.doi.org/
-
Activity of crizotinib (C) in patients (pts) with clear cell sarcoma (CCSA) in EORTC phase II trial 90101In: Journal of Clinical Oncology (JCO) Jg. 33 (2015) Nr. 15_suppl, S. 10542Online Volltext: dx.doi.org/ Online Volltext
-
Covalent-Allosteric Kinase InhibitorsIn: Angewandte Chemie International Edition Jg. 54 (2015) Nr. 35, S. 10313 - 10316Online Volltext: dx.doi.org/
-
Cytomegalovirus induces apoptosis in acute leukemia cells as a virus-versus-leukemia functionIn: Leukemia and Lymphoma Jg. 56 (2015) Nr. 11, S. 3189 - 3197Online Volltext: dx.doi.org/
-
EPAZ : A randomized phase II trial comparing pazopanib with doxorubicin as first line treatment in elderly patients with metastatic or advanced soft tissue sarcoma of the Working Group Medical Oncology (AIO) and German Interdisciplinary Sarcoma Group (GISG)In: Journal of Clinical Oncology (JCO) Jg. 33 (2015) Nr. 15_suppl, S. TPS10576Online Volltext: dx.doi.org/ Online Volltext
-
Emerging agents for the treatment of advanced, imatinib-resistant gastrointestinal stromal tumors : current status and future directionsIn: Drugs Jg. 75 (2015) Nr. 12, S. 1323 - 1334Online Volltext: dx.doi.org/ (Open Access)
-
Gastrointestinale Stromatumoren (GIST) : neues zu Pathologie, Chirurgie und medikamentöser TherapieIn: Zeitschrift für Gastroenterologie Jg. 53 (2015) Nr. 3, S. 235 - 243Online Volltext: dx.doi.org/
-
Inhibition of KIT-Glycosylation by 2-Deoxyglucose Abrogates KIT-Signaling and Combination with ABT-263 Synergistically Induces Apoptosis in Gastrointestinal Stromal TumorIn: PLoS ONE Jg. 10 (2015) Nr. 3, S. e0120531Online Volltext: dx.doi.org/ (Open Access)
-
Overcoming the proliferation rate paradox : Clinical evaluation of a continuous dosing scheme of the novel oral Eg5 inhibitor 4SC-205In: Journal of Clinical Oncology (JCO) Jg. 33 (2015) Nr. 15_suppl, S. 2528Online Volltext: dx.doi.org/ Online Volltext
-
Plasma sequencing to detect a multitude of secondary KIT resistance mutations in metastatic gastrointestinal stromal tumors (GIST)In: Journal of Clinical Oncology (JCO) Jg. 33 (2015) Nr. 15_suppl, S. 10518Online Volltext: dx.doi.org/ Online Volltext
-
Randomized, open-label, multicenter, phase III study of eribulin versus dacarbazine in patients (pts) with leiomyosarcoma (LMS) and adipocytic sarcoma (ADI)In: Journal of Clinical Oncology (JCO) Jg. 33 (2015) Nr. 15_suppl, S. LBA7005Online Volltext: dx.doi.org/ Online Volltext
-
Safety and efficacy of eltrombopag (EPAG) vs placebo (PBO) for treatment of chemotherapy (CTx)-induced thrombocytopenia (TCP) in patients (Pts) with solid tumors receiving gemcitabine (GEM)-based CTx : A phase 2 studyIn: Journal of Clinical Oncology (JCO) Jg. 33 (2015) Nr. 15_suppl, S. 9602Online Volltext: dx.doi.org/ Online Volltext
-
Targeted massively parallel sequencing of angiosarcomas reveals frequent activation of the mitogen activated protein kinase pathwayIn: OncoTarget Jg. 6 (2015) Nr. 34, S. 36041 - 36052Online Volltext: dx.doi.org/ (Open Access)
-
Three vs. 1 year of adjuvant imatinib (IM) for operable high-risk GIST : The second planned analysis of the randomized SSGXVIII/AIO trialIn: Journal of Clinical Oncology (JCO) Jg. 33 (2015) Nr. 15_suppl, S. 10505Online Volltext: dx.doi.org/ Online Volltext
-
Ziv-aflibercept in combination with FOLFIRI for 2nd-line treatment of patients with metastatic colorectal cancer : Interim safety data from the global aflibercept safety and quality-of-life program (ASQoP/AFEQT) in patients pretreated with bevacizumabIn: Journal of Clinical Oncology (JCO) Jg. 33 (2015) Nr. 15_suppl, S. e14686Online Volltext: dx.doi.org/ Online Volltext
-
miRNA-221 and miRNA-222 induce apoptosis via the KIT/AKT signalling pathway in gastrointestinal stromal tumoursIn: Molecular Oncology Jg. 9 (2015) Nr. 7, S. 1421 - 1433Online Volltext: dx.doi.org/ (Open Access)
-
Brain metastases in sarcoma patients : Incidence and outcomeIn: Journal of Clinical Oncology (JCO) Jg. 32 (2014) Nr. 15 Suppl., S. 10591Online Volltext: dx.doi.org/
-
Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma : An European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group randomised phase II and pharmacogenetiIn: European Journal of Cancer (EJC) Jg. 50 (2014) Nr. 2, S. 388 - 396Online Volltext: dx.doi.org/
-
Effect of secondary KIT mutations on growth of GIST cells in the absence of selective pressure by imatinib in isogenic models of imatinib resistanceIn: Journal of Clinical Oncology (JCO) Jg. 32 (2014) Nr. 15 Suppl., S. 10555Online Volltext: dx.doi.org/
-
First-in-human study of 4SC-205 (AEGIS), a novel oral inhibitor of Eg5 kinesin spindle proteinIn: Journal of Clinical Oncology (JCO) Jg. 32 (2014) Nr. 15 Suppl., S. 2564Online Volltext: dx.doi.org/
-
Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib - Analysis of prognostic factors (EORTC-STBSG collaborative study)In: European Journal of Surgical Oncology Jg. 40 (2014) Nr. 4, S. 412 - 419Online Volltext: dx.doi.org/
-
Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas : subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072In: Annals of Oncology Jg. 25 (2014) Nr. 3, S. 719 - 724Online Volltext: dx.doi.org/
-
Phase i study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumorsIn: British Journal of Cancer (BJC) Jg. 110 (2014) Nr. 5, S. 1155 - 1162Online Volltext: dx.doi.org/ (Open Access)
-
Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patientsIn: Clinical Cancer Research Jg. 20 (2014) Nr. 22, S. 5745 - 5755Online Volltext: dx.doi.org/
-
Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinibIn: Cancer Jg. 120 (2014) Nr. 15, S. 2325 - 2333Online Volltext: dx.doi.org/ (Open Access)
-
Successful resuscitation of a patient with ventricular fibrillation due to hypomagnesemia under cetuximab therapyIn: TumorDiagnostik & Therapie Jg. 35 (2014) Nr. 1, S. 25 - 27Online Volltext: dx.doi.org/
-
Targeting glucose metabolism by 2-deoxyglucose in gastrointestinal stromal tumorsIn: Cancer Research Jg. 74 (2014) Nr. 19 Suppl.,Online Volltext: dx.doi.org/
-
Ziv-aflibercept (Z) in combination with FOLFIRI for second-line treatment of patients (pts) with metastatic colorectal cancer (mCRC) : Interim safety data from the global aflibercept safety and quality-of-life program in pts pretreated with bevacizumab (B)In: Journal of Clinical Oncology (JCO) Jg. 33 (2014) Nr. 3 Suppl., S. 528Online Volltext: dx.doi.org/
-
Adjuvante Chemotherapie bei Weichteilsarkomen? Ein klares „Jein“In: Deutsche Medizinische Wochenschrift - DMW Jg. 138 (2013) Nr. 41, S. 2107 - 2110Online Volltext: dx.doi.org/
-
DOG1 Regulates Growth and IGFBP5 in Gastrointestinal Stromal TumorsIn: Cancer Research Jg. 73 (2013) Nr. 12, S. 3661 - 3670Online Volltext: dx.doi.org/
-
Detection of oncogenic kinase mutations in circulating plasma DNA and correlation with clinical benefit in the phase III GRID study of regorafenib vs placebo in TKI-refractory metastatic GISTIn: Cancer Research Jg. 73 (2013) Nr. Suppl. 8,Online Volltext: dx.doi.org/
-
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID) : an international, multicentre, randomised, placebo-controlled, phase 3 trialIn: Lancet Jg. 381 (2013) Nr. 9863, S. 295 - 302Online Volltext: dx.doi.org/
-
Feasibility of preemptive biomarker profiling for personalised early clinical drug development at a Comprehensive Cancer CenterIn: European Journal of Cancer (EJC) Jg. 49 (2013) Nr. 15, S. 3076 - 3082Online Volltext: dx.doi.org/
-
Free soluble HLA-G molecules but not exosome-derived soluble HLA-G molecules are of prognostic relevance in lung cancer patientsIn: Tissue Antigens Jg. 81 (2013) Nr. 5, S. 282 - 283Online Volltext: dx.doi.org/
-
IAP gene alterations and therapeutic modulation of IAPs by Smac mimetics in GIST
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie, 18.-22. Oktober 2013, Wien, Österreich,In: Onkologie Jg. 36 (2013) Nr. Suppl. 7, S. 245 - 246 -
LiposarcomasIn: Hematology/Oncology Clinics of North America Jg. 27 (2013) Nr. 5, S. 939 - 955Online Volltext: dx.doi.org/
-
Long-term responders and survivors on pazopanib for soft tissue sarcomas (STS) : Subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072In: Journal of Clinical Oncology (JCO) Jg. 31 (2013) Nr. 15 Suppl., S. 10553Online Volltext: dx.doi.org/
-
Mammalian target of rapamycin pathway activity in alveolar soft part sarcomaIn: Human Pathology Jg. 44 (2013) Nr. 10, S. 2266 - 2274Online Volltext: dx.doi.org/
-
Neoadjuvant Imatinib in Locally Advanced Gastrointestinal Stromal Tumors (GIST) : The EORTC STBSG ExperienceIn: Annals of Surgical Oncology Jg. 20 (2013) Nr. 9, S. 2937 - 2943Online Volltext: dx.doi.org/
-
Neoadjuvant treatment improves capsular integrity and the width of the fibrous capsule of high-grade soft-tissue sarcomasIn: European Journal of Surgical Oncology Jg. 39 (2013) Nr. 1, S. 61 - 67Online Volltext: dx.doi.org/
-
Pemetrexed in patients with refractory soft tissue sarcoma : a non-comparative multicenter phase II study of the German Sarcoma Group AIO-STS 005In: Investigational New Drugs: The Journal of New Anticancer Agents Jg. 31 (2013) Nr. 1, S. 167 - 174Online Volltext: dx.doi.org/
-
Safety, tolerability, and efficacy of the first-in-class antibody IMAB362 targeting claudin 18.2 in patients with metastatic gastroesophageal adenocarcinomasIn: Journal of Clinical Oncology (JCO) Jg. 31 (2013) Nr. 15 Suppl., S. 4080Online Volltext: dx.doi.org/
-
Secondary KIT mutations negatively impact cell growth in a novel isogenic model of imatinib-resistance in GIST
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie, 18.-22. Oktober 2013, Wien, Österreich,In: Onkologie Jg. 36 (2013) Nr. Suppl. 7, S. 178 - 179 -
Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib : A retrospective analysisIn: European Journal of Cancer Jg. 49 (2013) Nr. 5, S. 1027 - 1031Online Volltext: dx.doi.org/
-
Targeting gain of function and resistance mutations in Abl and KIT by hybrid compound designIn: Journal of Medicinal Chemistry Jg. 56 (2013) Nr. 14, S. 5757 - 5772Online Volltext: dx.doi.org/
-
The pathologic response of resected synovial sarcomas to hyperthermic isolated limb perfusion with melphalan and TNF-α : a comparison with the whole group of resected soft tissue sarcomasIn: World Journal of Surgical Oncology Jg. 11 (2013) Nr. 1, S. 185Online Volltext: dx.doi.org/ (Open Access)
-
Trabectedin in metastatic soft tissue sarcomas : Role of pretreatment and ageIn: International Journal of Oncology Jg. 43 (2013) Nr. 1, S. 23 - 28Online Volltext: dx.doi.org/
-
Use of ponatinib to inhibit kinase mutations associated with drug-resistant gastrointestinal stromal tumors (GIST)In: Journal of Clinical Oncology (JCO) Jg. 31 (2013) Nr. 15 Suppl., S. 10509Online Volltext: dx.doi.org/
-
Chemotherapy in resectable sarcomas with complex karyotypes - a single center retrospective analysisIn: Onkologie Jg. 35 (2012) Nr. Suppl. 6, S. 150 - 150
-
Eine endliche Geschichte : Was Barcelona, verstopfte Mäuse und Tumoren kleiner Kätzchen mit einem kleinen Wunder zu tun habenIn: Unikate: Berichte aus Forschung und Lehre (2012) Nr. 42: Translationale Krebsforschung: Auf dem Weg zu neuen Therapien, S. 98 - 105Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Growth patterns of lung metastases from sarcoma : prognostic and surgical implications from histologyIn: Interactive Cardiovascular and Thoracic Surgery Jg. 15 (2012) Nr. 4, S. 612 - 617Online Volltext: dx.doi.org/
-
Individualisierte Tumortherapie und Status quo beim MelanomIn: Onkologie Jg. 35 (2012) Nr. Suppl. 2, S. 2 - 6Online Volltext: dx.doi.org/
-
Inhibitors of Apoptosis Proteins (IAPs) in gastrointestinal stromal tumors - a therapeutic target?In: Onkologie Jg. 35 (2012) Nr. Suppl. 6, S. 249
-
Intimal sarcoma of the pulmonary artery with unusual findings : a case reportIn: Clinical Research in Cardiology Jg. 101 (2012) Nr. 5, S. 397 - 401Online Volltext: dx.doi.org/
-
Neutralization of pathogenic Gram-positive bacteria by macrophages is independent from TLR2,-3,-4,-7, and-9 yet depends upon MyD88In: Immunology Jg. 137 (2012) Nr. Suppl. 1, S. 299 - 299
-
One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor : a randomized trialIn: JAMA: Journal of the American Medical Association Jg. 307 (2012) Nr. 12, S. 1265 - 1272Online Volltext: dx.doi.org/
-
P53 modulation as a therapeutic strategy in gastrointestinal stromal tumorsIn: PLoS ONE Jg. 7 (2012) Nr. 5,Online Volltext: dx.doi.org/ (Open Access)
-
Phase I trial of panobinostat (P) and imatinib (IM) in patients with treatment-refractory gastrointestinal stromal tumors (GIST)In: Journal of Clinical Oncology (JCO) Jg. 30 (2012) Nr. Suppl. 15, S. 10032
-
Rechallenge with ifosfamide-containing regimen as salvage option for patients with metastatic soft tissue sarcomas progressing after multiple pretreatmentsIn: Journal of Clinical Oncology (JCO) Jg. 30 (2012) Nr. Suppl. 15,
-
Activity and side effects of imatinib in patients with gastrointestinal stromal tumors : data from a German multicenter trialIn: European Journal of Medical Research Jg. 16 (2011) Nr. 5, S. 206 - 212Online Volltext: dx.doi.org/ (Open Access)
-
Activity of eribulin mesylate in patients with soft-tissue sarcoma : a phase 2 study in four independent histological subtypesIn: Lancet Oncology Jg. 12 (2011) Nr. 11, S. 1045 - 1052Online Volltext: dx.doi.org/
-
Angiosarcomas of the adulthood - a large single center analysisIn: Onkologie Jg. 34 (2011) Nr. Suppl. 6, S. 254 - 254
-
Development of xenograft-based in vivo models of gastrointestinal stromal tumorsIn: Onkologie Jg. 34 (2011) Nr. Suppl. 6, S. 253 - 253
-
Growth patterns of lung metastases from sarcomasIn: Virchows Archiv Jg. 459 (2011) Nr. 2, S. 213 - 219Online Volltext: dx.doi.org/
-
Helical tomotherapy of soft tissue sarcoma-optimized soft-tissue preservation also acral TumorsIn: Strahlentherapie und Onkologie Jg. 187 (2011) Nr. Suppl. 1, S. 17 - 17
-
Inhibition of the Ras/Raf/MAPK-pathway in GIST : Therapeutic potential?In: Onkologie Jg. 34 (2011) Nr. Suppl. 6, S. 235 - 235
-
Postoperative FDG-PET/CT staging in GIST : Is there a benefit following R0 resection?In: European Journal of Radiology Jg. 80 (2011) Nr. 3, S. 670 - 674Online Volltext: dx.doi.org/
-
The BH3-mimetic ABT-263 enhances the apoptotic response of GIST cells to KIT-inhibitory treatmentsIn: Onkologie Jg. 34 (2011) Nr. Suppl. 6, S. 254
-
Trabectedin in heavily pretreated and elderly metastatic soft tissue sarcomas - a single center experienceIn: Onkologie Jg. 34 (2011) Nr. Suppl. 6, S. 237 - 237
-
Treatment of gastrointestinal stromal tumor after imatinib and sunitinibIn: Current Opinion in Oncology Jg. 23 (2011) Nr. 4, S. 367 - 372Online Volltext: dx.doi.org/
-
Tumor vascularization and histopathologic regression of soft tissue sarcomas treated with isolated limb perfusion with TNF-α and melphalanIn: Journal of Surgical Oncology Jg. 103 (2011) Nr. 5, S. 371 - 379Online Volltext: dx.doi.org/
-
A novel primary KIT exon 9 single nucleotide substitution c.1427G>T (p.Ser476Ile) in a gastrointestinal stromal tumorIn: Virchows Archiv Jg. 457 (2010) Nr. 5, S. 623 - 625Online Volltext: dx.doi.org/
-
Effective therapeutic sensitization of gastrointestinal stromal tumors by a BH3 mimeticIn: European Journal of Cancer / EJC Supplements Jg. 8 (2010) Nr. 7, S. 69 - 70Online Volltext: dx.doi.org/
-
Gastrointestinale Stromatumoren Epidemiologie, Ätiologie und PrognoseIn: TumorDiagnostik & Therapie Jg. 31 (2010) Nr. 5, S. 255 - 258Online Volltext: dx.doi.org/
-
Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib (IM)In: Journal of Clinical Oncology (JCO) Jg. 28 (2010) Nr. Suppl. 15, S. 10047Online Volltext: dx.doi.org/
-
MET overexpressing chordomas frequently exhibit polysomy of chromosome 7 but no MET activation through sarcoma-specific gene fusionsIn: Tumor Biology Jg. 31 (2010) Nr. 3, S. 157 - 163Online Volltext: dx.doi.org/
-
Proapoptotic activity of bortezomib in gastrointestinal stromal tumor cellsIn: Cancer Research Jg. 70 (2010) Nr. 1, S. 150 - 159Online Volltext: dx.doi.org/
-
Prognostic relevance of soluble human leukocyte antigen-G and total human leukocyte antigen class I molecules in lung cancer patientsIn: Human Immunology Jg. 71 (2010) Nr. 5, S. 489 - 495Online Volltext: dx.doi.org/
-
Therapeutic Potential of Mdm2 Inhibition in Malignant Germ Cell TumoursIn: European Urology Jg. 57 (2010) Nr. 4, S. 679 - 687Online Volltext: dx.doi.org/
-
Evaluation of 47 soft tissue sarcoma resection specimens after isolated limb perfusion with TNF-α and melphalan : Histologically characterized improved margins correlate with absence of recurrencesIn: Annals of Surgical Oncology Jg. 16 (2009) Nr. 3, S. 676 - 686Online Volltext: dx.doi.org/
-
Inhibitors of deacetylases suppress oncogenic KIT signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumorsIn: Cancer Research Jg. 69 (2009) Nr. 17, S. 6941 - 6950Online Volltext: dx.doi.org/ (Open Access)
-
Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinibIn: International Journal of Cancer Jg. 117 (2005) Nr. 2, S. 316 - 325Online Volltext: dx.doi.org/ (Open Access)
-
Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumorsIn: Journal of Nuclear Medicine Jg. 45 (2004) Nr. 3, S. 357 - 365
-
Response to imatinib mesylate of a gastrointestinal stromal tumor with very low expression of KITIn: Cancer Chemotherapy and Pharmacology Jg. 51 (2003) Nr. 3, S. 261 - 265Online Volltext: dx.doi.org/
-
Durvalumab and tremelimumab versus doxorubicin in previously untreated patients with advanced or metastatic soft tissue sarcoma : Patient-reported outcomes (PROs) of the randomized phase II MEDISARC study (AIO-STS-0415)In: Journal of Clinical Oncology (JCO) Jg. 42 (2024) Nr. Suppl. 16, 11519Online Volltext: dx.doi.org/
-
Efficacy, safety, and patient-reported outcomes of vimseltinib in patients with tenosynovial giant cell tumor : Results from the phase 3 MOTION trialIn: Journal of Clinical Oncology (JCO) Jg. 42 (2024) Nr. Suppl. 16, 11500Online Volltext: dx.doi.org/
-
INSIGHT: A phase 3, randomized, open-label study of ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib with KIT exon 11 + 17/18 mutationsIn: Journal of Clinical Oncology (JCO) Jg. 42 (2024) Nr. Suppl. 3, S. TPS767 - TPS767Online Volltext: dx.doi.org/
-
Overall survival and long-term safety with ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib : Final analyses from INTRIGUEIn: Journal of Clinical Oncology (JCO) Jg. 42 (2024) Nr. Suppl. 3, S. 748 - 748Online Volltext: dx.doi.org/
-
Peak study : A phase 3, randomized, open-label multicenter clinical study of bezuclastinib (CGT9486) and sunitinib in combination versus sunitinib in patients with gastrointestinal stromal tumors (GIST)In: Journal of Clinical Oncology (JCO) Jg. 42 (2024) Nr. Suppl. 3, TPS766Online Volltext: dx.doi.org/
-
StrateGIST 1 : A first-in-human (FIH), phase 1 study of IDRX-42 in patients with metastatic gastrointestinal stromal tumors resistant to prior treatment with tyrosine kinase inhibitors (TKIs)In: Journal of Clinical Oncology (JCO) Jg. 42 (2024) Nr. Suppl. 16, 11501Online Volltext: dx.doi.org/
-
68Ga-FAPI PET/CT novel diagnostic tool in sarcoma
Annual Congress of the European Association of Nuclear Medicine, 9-13 September 2023 Vienna, Austria,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 50 (2023) Nr. 1 supplement, S. S415Online Volltext: dx.doi.org/ (Open Access) -
Außergewöhnlicher Therapiebenefit von Imatinib bei cKIT-mutiertem Schleimhautmelanom mit nachfolgendem KIT-Mutationsverlust
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September 2023, Hamburg, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 21 (2023) Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 06.–09. September 2023 Hamburg, S. 21 - 22Online Volltext: dx.doi.org/ (Open Access) -
CDK4/6 inhibition in advanced chordoma : results from the NCT PMO-1601 trial
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 13. bis 16. Oktober 2023, Hamburg, Germany,In: Oncology Research and Treatment Jg. 46 (2023) Nr. Supplement 5: DGHO Abstracts, S. 153Online Volltext: dx.doi.org/ (Open Access) -
Fibroblast activation protein alpha (FAPα) directed imaging and radioligand therapy in patients with solitary fibrous tumor (SFT)In: Journal of Nuclear Medicine (JNM) Jg. 64 (2023) Nr. Suppl. 1, P714
-
Mutational heterogeneity of imatinib resistance and efficacy of ripretinib vs sunitinib in patients with gastrointestinal stromal tumor : ctDNA analysis from INTRIGUE
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 13. bis 16. Oktober 2023, Hamburg, Germany,In: Oncology Research and Treatment Jg. 46 (2023) Nr. Supplement 5: DGHO Abstracts, S. 154 - 156Online Volltext: dx.doi.org/ (Open Access) -
Mutational heterogeneity of imatinib resistance and efficacy of ripretinib vs sunitinib in patients with gastrointestinal stromal tumor : ctDNA analysis from INTRIGUEIn: Journal of Clinical Oncology (JCO) Jg. 41 (2023) Nr. Suppl. 36, 397784Online Volltext: dx.doi.org/
-
Occurence of hematotoxic side effects during 90Y-FAPI-46 radioligand therapy (RLT) in patients with advanced metastatic tumor diseases
Annual Congress of the European Association of Nuclear Medicine, 9-13 September 2023 Vienna, Austria,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 50 (2023) Nr. 1 supplement, S. S671Online Volltext: dx.doi.org/ (Open Access) -
Quality of life and self-reported function with ripretinib in ≥4th-line therapy for patients with gastrointestinal stromal tumors : analyses from INVICTUS
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 13. bis 16. Oktober 2023, Hamburg, Germany,In: Oncology Research and Treatment Jg. 46 (2023) Nr. Supplement 5: DGHO Abstracts, S. 153 - 154Online Volltext: dx.doi.org/ (Open Access) -
A phase II/III, randomized, open-label, multicenter study of BI 907828 compared to doxorubicin in the first-line treatment of patients with advanced dedifferentiated liposarcoma (DDLPS) : Brightline-1In: Journal of Clinical Oncology (JCO) Jg. 40 (2022) Nr. 16_Suppl., S. TPS11586Online Volltext: dx.doi.org/
-
CDK4/6 inhibition in locally advanced/metastatic chordoma (NCT PMO-1601)In: Annals of Oncology Jg. 33 (2022) Nr. Suppl. 7, S. 1228Online Volltext: dx.doi.org/ (Open Access)
-
Circulating tumor DNA (ctDNA) analyses of the phase III VOYAGER trial : KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor (GIST)In: Journal of Clinical Oncology (JCO) Jg. 40 (2022) Nr. 16_Suppl., S. 101Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Die präoperative Radiotherapie vermindert das Lokalrezidivrisiko bei fortgeschrittenen Synovialsarkomen am effektivsten : Untersuchungen zum Einsatz der Strahlentherapie im multimodalen Therapiekonzept
28. Kongress der Deutschen Gesellschaft für Radioonkologie ; DEGRO 2022 ; 26. bis 28.05.2022, Stuttgart, Germany,In: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 198 (2022) Nr. Supplement 1, S. S34 - S35Online Volltext: dx.doi.org/ (Open Access) -
INTRIGUE : eine randomisierte, offene Phase-3-Studie zur Bewertung der Wirksamkeit und Sicherheit von Ripretinib im Vergleich zu Sunitinib bei Patienten mit fortgeschrittenem gastrointestinalem Stromatumor, die zuvor mit Imatinib behandelt wurden
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 7.–10. Oktober 2022, Wien, Austria,In: Oncology Research and Treatment Jg. 45 (2022) Nr. Supplement 2, S. 263Online Volltext: dx.doi.org/ (Open Access) -
INTRIGUE: A phase III, randomized, open-label study to evaluate the efficacy and safety of ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinibIn: Journal of Clinical Oncology (JCO) Jg. 40 (2022) Nr. 36, S. 359881 - 359881Online Volltext: dx.doi.org/
-
KIT resistance mutations identified by circulating tumor DNA and treatment outcomes in advanced gastrointestinal stromal tumorIn: Journal of Clinical Oncology (JCO) Jg. 40 (2022) Nr. 16_Suppl., S. 11514Online Volltext: dx.doi.org/
-
Patient reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after imatinib treatment in INTRIGUE : A phase 3 open-label studyIn: Journal of Clinical Oncology (JCO) Jg. 40 (2022) Nr. 16_Suppl., S. 11541Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Protonentherapie der retroperitonealen Sarkome : Ergebnisse der prospektiven Registerstudien ProReg und KiProReg
28. Kongress der Deutschen Gesellschaft für Radioonkologie ; DEGRO 2022 ; 26. bis 28.05.2022, Stuttgart, Germany,In: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 198 (2022) Nr. Supplement 1, S. S28Online Volltext: dx.doi.org/ (Open Access) -
Safety and efficacy of [90Y]Y-FAPI-46 radioligand therapy in patients with advanced sarcomas and other cancer entities
ESMO Congress 2022, 9 - 13 September 2022, Paris, France,In: Annals of Oncology Jg. 33 (2022) Nr. Supplement 7: Abstract Book of the ESMO Congress 2022, 9 - 13 September 2022, S. S1231 - S1232Online Volltext: dx.doi.org/ (Open Access) -
Urogenitale Sarkome im Erwachsenenalter : eine populationsbasierte Analyse von Tumorcharakteristika, Inzidenz und Überleben in Nordrhein-Westfalen (NRW)
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 7.–10. Oktober 2022, Wien, Austria,In: Oncology Research and Treatment Jg. 45 (2022) Nr. Supplement 2, S. 63Online Volltext: dx.doi.org/ (Open Access) -
A novel theranostic approach for sarcoma : Insights on diagnostic and therapeutic use of FAP-radioligands
Gemeinsame Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 01.-04. Oktober 2021, Hybrid-Kongress,In: Oncology Research and Treatment Jg. 44 (2021) Nr. Supplement 2, S. 11 - 12Online Volltext: dx.doi.org/ (Open Access) -
A post hoc analysis of the EPAZ trial : The prognostic role of geriatric variables in elderly soft tissue sarcoma (STS) patientsIn: Annals of Oncology Jg. 32 (2021) Nr. Suppl. 5, S. 1125 - S1126Online Volltext: dx.doi.org/ (Open Access)
-
Clinical benefit with ripretinib as ≥4th line treatment in patients with advanced gastrointestinal stromal tumors (GIST) : Update from the phase III INVICTUS study
Gemeinsame Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 01.-04. Oktober 2021, Hybrid-Kongress,In: Oncology Research and Treatment Jg. 44 (2021) Nr. Supplement 2, S. 11Online Volltext: dx.doi.org/ (Open Access) -
Gene expression-based prediction of pazopanib benefit in sarcomasIn: Annals of Oncology Jg. 32 (2021) Nr. Suppl. 5, S. 1117Online Volltext: dx.doi.org/ (Open Access)
-
Initial clinical experience with [Y-90]Y-FAPI-46 radioligand therapy for advanced stage solid tumorsIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 48 (2021) Nr. Suppl. 1, S. 290
-
Phase I study of ripretinib, a broad-spectrum KIT and PDGFRA inhibitor, in patients with KIT-mutated or KIT-amplified melanomaIn: Annals of Oncology Jg. 32 (2021) Nr. Suppl. 5, S. 896 - S897Online Volltext: dx.doi.org/ (Open Access)
-
Proton Therapy for Patients with primary Bone Tumors in the Pelvic and Lumbar Regions : Results of the prospective Registry Studies PrroReg and KiProRegIn: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 197 (2021) Nr. Suppl. 1, S. 24
-
Ripretinib as ≥4th-line treatment in patients with advanced gastrointestinal stromal tumor : Long-term update from the phase III INVICTUS studyIn: Annals of Oncology Jg. 32 (2021) Nr. Suppl. 5, S. 1120 - S1121Online Volltext: dx.doi.org/ (Open Access)
-
1659P AI-based grading approach identifies FNCLCC grade 3 soft tissue sarcomasIn: Annals of Oncology Jg. 31 (2020) Nr. Suppl. 4, S. S988Online Volltext: dx.doi.org/ (Open Access)
-
Comprehensive genomic analysis of rare cancers : Results of the MASTER precision oncology trial of the German Cancer Consortium
AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, USA,In: Cancer Research Jg. 80 (2020) Nr. Suppl. 16, S. 821Online Volltext: dx.doi.org/ -
Comprehensive profile of platelet derived growth factor receptor alpha (PDGFRA) mutations in gastrointestinal stromal tumors
Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, USA,In: Cancer Research Jg. 80 (2020) Nr. 16: Supplement, S. 3005Online Volltext: dx.doi.org/ -
Efficacy and safety of ripretinib as ≥4th-line therapy for patients with gastrointestinal stromal tumor following crossover from placebo : Analyses from INVICTUSIn: Annals of Oncology Jg. 31 (2020) Nr. Suppl. 3, S. 236Online Volltext: dx.doi.org/ (Open Access)
-
Long-term efficacy, tolerability and overall survival in patients (pts) with unresectable or metastatic (U/M) PDGFRA D842V-mutant gastrointestinal stromal tumour (GIST) treated with avapritinib : NAVIGATOR phase I trial update
ESMO Asia Virtual Congress 2020 ; 20-22 November 2020,In: Annals of Oncology Jg. 31 (2020) Nr. Supplement 6, S. S1287 - S1288Online Volltext: dx.doi.org/ (Open Access) -
Long-term efficacy, tolerability, and overall survival in patients with unresectable or metastatic platelet-derived growth factor receptor A (PDGFRA) D842V-mutant gastrointestinal stromal tumors (GIST) treated with avapritinib : NAVIGATOR phase 1 trial update
Virtuelle Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 09.–11. Oktober 2020,In: Oncology Research and Treatment Jg. 43 (2020) Nr. Suppl. 4, S. 227Online Volltext: dx.doi.org/ (Open Access) -
Lower-dosing ponatinib in pre-treated GIST : Results of the POETIG phase II trialIn: Journal of Clinical Oncology (JCO) Jg. 38 (2020) Nr. 15_Suppl., S. 11536Online Volltext: dx.doi.org/
-
Patient journey and quality of life (QOL) among diffuse-type TGCT in the US
2020 ASCO Annual Meeting; 29.05.2020 - 02.06.2020; Chicago, USA,In: Journal of Clinical Oncology (JCO) Jg. 38 (2020) Nr. Suppl. 15, S. e23565Online Volltext: dx.doi.org/ (Open Access) -
Protonentherapie bei Chondrosarkomen der Schädelbasis : Erste Ergebnisse der prospektiven Register ProReg und KiProReg zu Verträglichkeit und Outcome
26. Jahrestagung der Deutschen Gesellschaft für Radioonkologie (DEGRO) ; 24. Juni - 28. Juni 2020, Wiesbaden, Germany,In: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 196 (2020) Nr. 1 Supplement: Abstracts DEGRO 2020, S. S95Online Volltext: dx.doi.org/ (Open Access) -
Role of adjuvant imatinib dose in radically resected GIST harboring KIT exon 9 mutationsIn: Journal of Clinical Oncology (JCO) Jg. 38 (2020) Nr. 15_Suppl., S. 11533Online Volltext: dx.doi.org/
-
Think twice : Anemia of chronic disease (ACD) due to angiomatoid fibrous histiocytoma (AFH)
Virtuelle Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 09.–11. Oktober 2020,In: Oncology Research and Treatment Jg. 43 (2020) Nr. Suppl. 4, S. 181Online Volltext: dx.doi.org/ (Open Access) -
Three versus one year of adjuvant imatinib for high-risk gastrointestinal stromal tumor (GIST) : Survival analysis of a randomized trial after 10 years of follow-upIn: Journal of Clinical Oncology (JCO) Jg. 38 (2020) Nr. 15_Suppl., S. 11503Online Volltext: dx.doi.org/
-
Clinical relevance of comprehensive genomic analysis in advanced-stage cancers and rare malignancies : Results from the MASTER trial of the German Cancer ConsortiumIn: Cancer Research Jg. 79 (2019) Nr. Suppl. 13,Online Volltext: dx.doi.org/
-
Comprehensive genomic and transcriptomic profiling of gastrointestinal stromal tumorsIn: Cancer Research Jg. 79 (2019) Nr. Suppl. 13,Online Volltext: dx.doi.org/
-
Extraordinary response to a combination therapy with Dabrafenib and Trametinib in a malignant extrarenal rhabdoid tumor of the liver in adult : a call for precision oncology in sarcomas
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 11. - 14. Oktober 2019, Berlin, Germany,In: Oncology Research and Treatment Jg. 42 (2019) Nr. Supplement 4: Abstracts, S. 293Online Volltext: dx.doi.org/ (Open Access) -
MARkers for ImmunotherApy in sarcomas (the MARIAchIS-project) : what can we learn from responders?
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 11. - 14. Oktober 2019, Berlin,In: Oncology Research and Treatment Jg. 42 (2019) Nr. Supplement 4: Abstracts, S. 292Online Volltext: dx.doi.org/ (Open Access) -
Monocentric analysis to identify clinical prognostic factors for angiosarcoma
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 11. - 14. Oktober 2019, Berlin, Germany,In: Oncology Research and Treatment Jg. 42 (2019) Nr. Supplement 4: Abstracts, S. 138Online Volltext: dx.doi.org/ (Open Access) -
VOYAGER : an open-label, randomised, phase 3 study of avapritinib vs regorafenib in patients with locally advanced metastatic or unresectable gastrointestinal stromal tumour
ESMO 21st World Congress on Gastrointestinal Cancer ; Barcelona, 03–06 July 2019,In: Annals of Oncology Jg. 30 (2019) Nr. Suppl. 4, S. iv54Online Volltext: dx.doi.org/ (Open Access) -
What is the best therapy for grossly resected synovial sarcoma? : Experience of the CWS Study GroupIn: Journal of Clinical Oncology (JCO) Jg. 37 (2019) Nr. 15, S. 10042 - 10042Online Volltext: dx.doi.org/ (Open Access)
-
Activity and safety of crizotinib in patients with advanced, metastatic alveolar soft part sarcoma (ASPS) with rearrangement of TFE3 : European Organization for Research and Treatment of Cancer (EORTC) phase 2 trial 90101 CREATEIn: Journal of Clinical Oncology (JCO) Jg. 36 (2018) Nr. 15 Suppl., S. 11540Online Volltext: dx.doi.org/ (Open Access)
-
Angiosarkom im Bereich des Capillitium mit der Symptomatik eines Quincke‐Ödems
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. Suppl. 6, S. 34Online Volltext: dx.doi.org/ (Open Access) -
CDK4/6 inhibition in locally advanced/metastatic chordoma (NCT-PMO-1601)
33. Deutscher Krebskongress - Perspektiven verändern Krebs - Krebs verändert Perspektiven. Diagnose - Therapie - (Über-)Leben ; 21.-24. Februar 2018, Berlin,In: Oncology Research and Treatment Jg. 41 (2018) Nr. Suppl. 1, S. 156Online Volltext: dx.doi.org/ (Open Access) -
Circulating tumor DNA in patients with Gastrointestinal Stromal Tumor (GIST) and activating mutations of cKIT or PDGFR alpha : final results from the multi-center CF-DNA GIST trial
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 28. September - 2. Oktober 2018, Wien,In: Oncology Research and Treatment Jg. 41 (2018) Nr. Suppl. 4, S. 124Online Volltext: dx.doi.org/ (Open Access) -
Clear Cell Sarcoma - a rare Differential Diagnosis of malignant MelanomaIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. Suppl. 6, S. 3
-
Correlation of ctDNA and response in patients (pts) with PDGFR alpha D842 GIST treated with avapritinibIn: Annals of Oncology Jg. 29 (2018) Nr. Suppl. 8, S. 584
-
Effect of crizotinib on disease control in patient with advanced papillary renal cell carcinoma type 1 with MET mutations or amplification : Final results of EORTC 90101 CREATEIn: Journal of Clinical Oncology (JCO) Jg. 36 (2018) Nr. 6 Suppl., S. 580 - 580Online Volltext: dx.doi.org/ (Open Access)
-
Final results of ENLIVEN : A global, double-blind, randomized, placebo-controlled, phase 3 study of pexidartinib in advanced tenosynovial giant cell tumor (TGCT)In: Journal of Clinical Oncology (JCO) Jg. 36 (2018) Nr. Suppl. 15, S. 11502 - 11502Online Volltext: dx.doi.org/ (Open Access)
-
First prospective observational study in diffuse-type tenosynovial giant cell tumors.In: Journal of Clinical Oncology (JCO) Jg. 36 (2018) Nr. 15 Suppl., S. 11560Online Volltext: dx.doi.org/ (Open Access)
-
Klarzellsarkom – eine seltene Differentialdiagnose des malignen Melanoms
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 3Online Volltext: dx.doi.org/ (Open Access) -
Phase 1b results of avelumab in patients (pts) with previously treated metastatic melanoma enrolled in the JAVELIN Solid Tumor trial, including updated subgroup analysesIn: Journal of Clinical Oncology (JCO) Jg. 36 (2018) Nr. 15 Suppl., S. e21531Online Volltext: dx.doi.org/ (Open Access)
-
Randomized Phase 2 Study of Trabectedin/Olaparib Compared to Physician‘s Choice in Subjects with Previously Treated Advanced or Recurrent Solid Tumors Haboring DNA Repair Deficiencies (DKTK/NCT-PMO-1603, TOP-ART
33. Deutscher Krebskongress - Perspektiven verändern Krebs - Krebs verändert Perspektiven. Diagnose - Therapie - (Über-)Leben ; 21.-24. Februar 2018, Berlin,In: Oncology Research and Treatment Jg. 41 (2018) Nr. Suppl. 1, S. 120 - 121Online Volltext: dx.doi.org/ (Open Access) -
Randomized comparison of pazopanib (PAZ) and doxorubicin (DOX) in the first line treatment of metastatic soft tissue sarcoma (STS) in elderly patients (pts) : Results of a phase II study (EPAZ)In: Journal of Clinical Oncology (JCO) Jg. 36 (2018) Nr. Suppl. 15, S. 11506 - 11506Online Volltext: dx.doi.org/ (Open Access)
-
Randomized phase II trial of trofosfamide vs. adriamycin in elderly patients with previously untreated metastatic soft tissue sarcomaIn: Journal of Clinical Oncology (JCO) Jg. 36 (2018) Nr. Suppl. 15, S. 11507 - 11507Online Volltext: dx.doi.org/ (Open Access)
-
Results of a dose- and regimen-finding Phase Ib study of HDM201 in combination with ribociclib in patients with locally advanced or metastatic liposarcomaIn: Cancer Research Jg. 78 (2018) Nr. Suppl. 13,Online Volltext: dx.doi.org/
-
Targeting the PI3K-and MAPK pathway in high grade leiomyosarcoma
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 28. September - 2. Oktober 2018, Wien,In: Oncology Research and Treatment Jg. 41 (2018) Nr. Suppl. 4, S. 300Online Volltext: dx.doi.org/ (Open Access) -
Treatment of angiosarcoma with pazopanib and paclitaxel : Results of the phase II trial of the German Interdisciplinary Sarcoma Group (GISG-06 EVA) studyIn: Journal of Clinical Oncology (JCO) Jg. 36 (2018) Nr. 15 Suppl., S. 11570Online Volltext: dx.doi.org/ (Open Access)
-
Validation of the new UICC classification (8th ed.) for the staging of GIST in the TKI eraIn: Journal of Clinical Oncology (JCO) Jg. 36 (2018) Nr. Suppl. 15, S. e23517 - e23517Online Volltext: dx.doi.org/ (Open Access)
-
First-in-human study of IMAB362, an anti-claudin 18.2 monoclonal antibody, in patients with advanced gastroesophageal cancerIn: Annals of Oncology Jg. 28 (2017) Nr. Suppl. 5,
-
PD-L1 inhibition - a new therapeutic opportunity in cutaneous angiosarcoma?In: Annals of Oncology Jg. 28 (2017) Nr. Suppl. 5,
-
Longitudinal analysis of the impact of the introduction of tyrosine kinase inhibitor therapy on overall survival of patients with gastrointestinal stromal tumors treated at the West German Cancer Center
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 9.-13. Oktober 2015, Basel, Schweiz,In: Oncology Research and Treatment Jg. 38 (2015) Nr. Suppl. 5, S. 167 - 167Online Volltext: dx.doi.org/ -
Solitary fibrous tumors/haemangiopericytoma : Analysis of prognostic factors of 28 patients from a high volume sarcoma center
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 9.-13. Oktober 2015, Basel, Schweiz,In: Oncology Research and Treatment Jg. 38 (2015) Nr. Suppl. 5, S. 246Online Volltext: dx.doi.org/ -
TNM-classification for clear cell sarcomas - is it useful?
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 9.-13. Oktober 2015, Basel, Schweiz,In: Oncology Research and Treatment Jg. 38 (2015) Nr. Suppl. 5, S. 247 - 248Online Volltext: dx.doi.org/ -
Health-related quality of life (HRQoL) of patients with advanced gastrointestinal stromal tumors (GIST) treated with regorafenib (REG) vs placebo (P) in the phase III GRID trial
31. Deutscher Krebskongress iKON - intelligente Konzepte in der Onkologie, 19.-22. Februar 2014, Berlin,In: Oncology Research and Treatment Jg. 37 (2014) Nr. Suppl. 1, S. 58Online Volltext: dx.doi.org/ -
Systemic treatment of metastatic uveal melanoma - a silver lining on the horizon?
31. Deutscher Krebskongress iKON - intelligente Konzepte in der Onkologie, 19.-22. Februar 2014, Berlin,In: Oncology Research and Treatment Jg. 37 (2014) Nr. Suppl. 1, 31. Deutscher Krebskongress iKON - intelligente Konzepte in der Onkologie Berlin, 19.-22. Februar 2014: Abstracts, S. 118 - 119Online Volltext: dx.doi.org/ -
Time course of adverse events in the phase III GRID study of regorafenib in patients with metastatic gastrointestinal stromal tumors (GIST)In: Oncology Research and Treatment Jg. 37 (2014) Nr. Suppl. 1, S. 58 - 59Online Volltext: dx.doi.org/ (Open Access)
-
WTZ-Tumorprofil-A preemptive biomarker profiling program in relation to personalized clinical drug development at a large German Comprehensive Cancer Center : Two years experience
31. Deutscher Krebskongress iKON - intelligente Konzepte in der Onkologie, 19.-22. Februar 2014, Berlin,In: Oncology Research and Treatment Jg. 37 (2014) Nr. Suppl. 1, S. 2 - 3Online Volltext: dx.doi.org/ -
Brain metastases in soft tissue sarcoma patients - incidence, prognosis and outcome
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie, 18.-22. Oktober 2013, Wien, Österreich,In: Onkologie Jg. 36 (2013) Nr. Suppl. 7, S. 181Online Volltext: dx.doi.org/ -
Interim analysis of a phase II study to evaluate imatinib mesylate to induce progression arrest in aggressive fibromatosis/desmoid tumors not amenable to surgical resection with R0 intent or accompanied by unacceptable function loss - A study of the German Interdisciplnary Sarcoma Group (GISG)
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie, 18.-22. Oktober 2013, Wien, Österreich,In: Onkologie Jg. 36 (2013) Nr. Suppl. 7, S. 180Online Volltext: dx.doi.org/ -
Results from a phase III trial (GRID) evaluating regorafenib in metastatic gastrointestinal stromal tumour (GIST) : Subgroup analysis of outcomes based on pretreatment characteristics
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie, 18.-22. Oktober 2013, Wien, Österreich,In: Onkologie Jg. 36 (2013) Nr. Suppl. 7, S. 180 - 181Online Volltext: dx.doi.org/ -
Targeting glucose metabolism by 2-Deoxyglucose in Gastrointestinal Stromal Tumors
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie, 18.-22. Oktober 2013, Wien, Österreich,In: Onkologie Jg. 36 (2013) Nr. Suppl. 7, S. 246Online Volltext: dx.doi.org/ -
Functional characterization of DOG1 in Gastrointestinal Stromal Tumors (GIST)In: Cancer Research Jg. 72 (2012) Nr. 8, Suppl., S. 1824Online Volltext: dx.doi.org/
-
Inhibitors of apoptosis (IAPs) in gastrointestinal stromal tumorsIn: Cancer Research Jg. 72 (2012) Nr. 8, Suppl., S. 3855 - 3855Online Volltext: dx.doi.org/
-
Cytomegalovirus increases incidence of acute GvHD and reduces the relapse risk for acute leukaemia after transplant : there is a virus-versus-leukaemia effect
EBMT (European Group for Blood and Bone Marrow Transplantation) 2010. March 21-14, 2010. Vienna, Austria,In: Bone Marrow Transplantation Jg. 45 (2010) Nr. Suppl. 2, S. S79Online Volltext: dx.doi.org/ -
Final analysis of a non-comparative phase II study of multi target enzyme inhibitor pemetrexed in patients with refractory soft tissue sarcoma : German Sarcoma Group / AIO 005
Strukturen verändern – Heilung verbessern ; 29. Deutscher Krebskongress ; 24.-27. Februar 2010, Berlin,In: Oncology Research and Treatment Jg. 33 (2010) Nr. Suppl. 2, S. 53Online Volltext: dx.doi.org/ -
Metastasectomy in patients with GIST in the era of imatinib - improved survival?
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie. Berlin, 1.–5. Oktober 2010,In: Onkologie Jg. 33 (2010) Nr. Suppl. 6, S. 108Online Volltext: dx.doi.org/ -
Predictive Biomarkers and Targeted Therapies in SarcomasIn: Predictive Biomarkers in Oncology: Applications in Precision Medicine / Badve, Sunil; Kumar, George Louis (Hrsg.) 2018, S. 475 - 492Online Volltext: dx.doi.org/
-
Deep molecular profiling of advanced synovial sarcoma as a basis for interventional clinical trials
ESMO Congress 2023 ; 20 - 24 October 2023, Madrid, Spain,In: Annals of Oncology Jg. 34 (2023) Nr. Supplement 2: Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023, S. S1042Online Volltext: dx.doi.org/ -
Therapieansprechen auf Sunitinib bei Imatinib-resistentem Rezidiv eines Dermatofibrosarkoma protuberans am Capillitium
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September 2023, Hamburg, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 21 (2023) Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 06.–09. September 2023 Hamburg, S. 99 - 100Online Volltext: dx.doi.org/ (Open Access) -
Value of broad molecular profiling for cancer diagnosis
ESMO Congress 2023 ; 20 - 24 October 2023, Madrid, Spain,In: Annals of Oncology Jg. 34 (2023) Nr. Supplement 2: Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023, S. S1184Online Volltext: dx.doi.org/ (Open Access) -
Evaluation of mismatch repair deficiency as predictive biomarker in novel sarcoma cell line models
Gemeinsame Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 01.-04. Oktober 2021, Hybrid-Kongress,In: Oncology Research and Treatment Jg. 44 (2021) Nr. Supplement 2, S. 186Online Volltext: dx.doi.org/ (Open Access) -
Safety profile of ripretinib, including impact of alopecia, and Palmar-Plantar Erythrodysesthesia Syndrome (PPES) on patient-reported outcomes (PROs), in ≥ fourth-line advanced gastrointestinal stromal tumors (GIST) : Analyses from INVICTUS
Gemeinsame Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 01.-04. Oktober 2021, Hybrid-Kongress,In: Oncology Research and Treatment Jg. 44 (2021) Nr. Supplement 2, S. 186 - 187Online Volltext: dx.doi.org/ (Open Access) -
Chemotherapie bei resektablen Weichteilsarkomen mit komplexem Karyotyp : eine Single-Center Analyse
The annual meeting of the German, Austrian and Swiss Society of Haematology and Oncology, 19.-23.10.2013, Stuttgart,Stuttgart (2013)